Market Pulse Archives

April 1, 2020, 6:32 a.m. EDT

Keros Therapeutics sets IPO terms, expects to raise up to $80 million

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Keros Therapeutics Inc. (KROS)
  • X
    Renaissance IPO ETF (IPO)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Keros Therapeutics /zigman2/quotes/217766474/composite KROS -4.98% has set terms of its initial public offering, in which it expects to raise up to $80 million, and be valued at about $291 million. The biopharmaceutical company, which is developing treatments for hematological and musculoskeletal disorders, if offering 5 million shares for sale with the IPO expected to price between $14 and $16 a share. The stock is expected to be listed on the Nasdaq exchange under the ticker symbol "KROS." Jefferies, SVB Leerink and Piper Sandler are the joint book-running managers. The company recorded a net loss of $14.1 million on revenue of $10 million in 2019 after a loss of $2.3 million on revenue of $10 million in 2018. Keros is looking to go public at a time that the Renaissance IPO ETF /zigman2/quotes/207665280/composite IPO +0.11% has lost 15.3% over the past three months and the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.18% has dropped 20.0%.

US : U.S.: Nasdaq
$ 74.02
-3.88 -4.98%
Volume: 131,894
Dec. 2, 2020 4:00p
P/E Ratio
Dividend Yield
Market Cap
$1.49 billion
Rev. per Employee
US : U.S.: NYSE Arca
$ 62.44
+0.07 +0.11%
Volume: 293,771
Dec. 2, 2020 8:00p
+6.56 +0.18%
Volume: 2.37B
Dec. 2, 2020 5:07p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.